Safety and efficacy of subcutaneous ianalumab (VAY736) in patients with primary Sjögren's syndrome: a randomised, double-blind, placebo-controlled, phase 2b dose-finding trial-Reference-Cited by-同舟云学术

Safety and efficacy of subcutaneous ianalumab (VAY736) in patients with primary Sjögren's syndrome: a randomised, double-blind, placebo-controlled, phase 2b dose-finding trial

Published:2022-01 Issue:10320 Volume:399 Page:161-171
ISSN:0140-6736
Container-title:The Lancet
language:en
Short-container-title:The Lancet

Author:

Bowman Simon J,Fox Robert,Dörner Thomas,Mariette Xavier,Papas Athena,Grader-Beck Thomas,Fisher Benjamin A,Barcelos Filipe,De Vita Salvatore,Schulze-Koops Hendrik,Moots Robert J,Junge Guido,Woznicki Janice N,Sopala Monika A,Luo Wen-Lin,Hueber Wolfgang

Funder

Novartis AG

Publisher

Elsevier BV

Subject

General Medicine

Reference24 articles.

1. Primary Sjögren's syndrome;Mariette;N Engl J Med,2018

2. Treatment of primary Sjögren syndrome: a systematic review;Ramos-Casals;JAMA,2010

3. New treatment guidelines for Sjögren's disease;Vivino;Rheum Dis Clin North Am,2016

4. Multiple roles for B-lymphocytes in Sjogren's syndrome;Ambrus;J Clin Med,2016

5. B cells in the pathogenesis of primary Sjögren syndrome;Nocturne;Nat Rev Rheumatol,2018

Cited by 102 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Management of Sjögren disease syndrome;Dubois' Lupus Erythematosus and Related Syndromes;2025

2. Pathogenesis of Sjögren syndrome;Dubois' Lupus Erythematosus and Related Syndromes;2025

3. The role of cytokines from salivary gland epithelial cells in the immunopathology of Sjögren’s syndrome;Frontiers in Immunology;2024-09-13

4. Precision medicine in Sjögren's disease;The Lancet Rheumatology;2024-09

5. Lupus Nephritis from Pathogenesis to New Therapies: An Update;International Journal of Molecular Sciences;2024-08-18